The Journal of Trauma: Injury, Infection, and Critical Care · 2016 · 83 citations · 16 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPerioperative Quality ImprovementTrauma CareAnticoagulant ManagementAnticoagulation ManagementPharmacokinetics In Critical IllnessThromboembolism PreventionThrombosis ManagementThrombosis PreventionDose Adjustment AssessmentDose Adjustment CriteriaProphylactic EfficacyProtocol-specific DosingThromboprophylaxis In Critical IllnessThromboprophylaxis In Hospitalized PatientsThromboprophylaxis In Trauma PatientsVenous Thromboembolism Assessment
BACKGROUND: Empiric enoxaparin dosing is inadequate for most trauma patients, leading to below target initial anti-Xa levels and requiring dose adjustment for optimal venous thromboembolism prophylaxis. We hypothesize that patient factors affecting initial anti-Xa levels can be identified based on drug pharmacokinetics, allowing creation of a new dosing protocol that will provide a higher percentage of in-target (0.2-0.4 IU/mL) patients at initial anti-Xa level assessment. METHODS: Records of 318 trauma patients were evaluated, and NONMEM and PSN software were used to analyze 11 variables for their effects on anti-Xa levels. Computer modeling was used to select a new dosing protocol, which was implemented on the trauma service as a quality improvement project. The first 145 patients appropriately enrolled were assessed for response and complications. RESULTS: Only 29.5% of the pre-intervention group had initial anti-Xa levels in the appropriate prophylactic range (). Levels were most strongly influenced by patient weight, outweighing contributions from all other variables. A new regimen for initial dosing was therefore designed with three weight-defined categories for ease of administration. The post-intervention group showed an increase in in-target initial anti-Xa levels to 74.5% (p < 0.001), with a corresponding decrease in subprophylactic patients from 68.0% to 20.7%. There was an increase in supraprophylactic levels to 4.8%, but no supraprophylactic patients had hemorrhagic complications.(Figure is included in full-text article.) CONCLUSIONS: Implementation of a new, categorized, weight-based enoxaparin dosing protocol was safe and significantly improved the percentage of trauma patients with in-target anti-Xa levels on initial assessment. Further studies are needed to determine whether such dosing decreases venous thromboembolism rates. LEVEL OF EVIDENCE: Therapeutic/care management study, level II.
16
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
P. Prandoni · Annals of Internal Medicine · 1996 · 2.1K citations
A Prospective Study of Venous Thromboembolism after Major Trauma
William Geerts, Karen I. Code, Erluo Chen · New England Journal of Medicine · 1994 · 1.4K citations · Full text
Medicine, Hematology, Surgery +17
A Prospective Study of Venous Thromboembolism After Major Trauma
Peggy Hollingsworth-Fridlund, W. Geerts, Karen I. Code et al. · Journal of Trauma Nursing · 1997 · 1.1K citations
Medicine, Hematology, Surgery +17
Sam Schulman, Per Lindmarker, Margareta Holmström et al. · Journal of Thrombosis and Haemostasis · 2006 · 507 citations